Oxford BioDynamics (STU:LMQ) EBIT: €-13.04 Mil (TTM As of Sep. 2025)


What is Oxford BioDynamics EBIT?

Oxford BioDynamics STU:LMQ EBIT is €-13.04 Mil as of Sep. 2025. The stock has 4 warning signs investors should review.

Oxford BioDynamics's earnings before interest and taxes (EBIT) for the six months ended in Sep. 2025 was €-6.26 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2025 was €-13.04 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Oxford BioDynamics's annualized ROC % for the quarter that ended in Sep. 2025 was -125.51%. Oxford BioDynamics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2025 was -201.30%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Oxford BioDynamics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2025 was -106.23%.

Oxford BioDynamics  (STU:LMQ) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Oxford BioDynamics's annualized ROC % for the quarter that ended in Sep. 2025 is calculated as:

ROC % (Q: Sep. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2025 ) + Invested Capital (Q: Sep. 2025 ))/ count )
=-11.216 * ( 1 - 2.31% )/( (8.964 + 8.496)/ 2 )
=-10.9569104/8.73
=-125.51 %

where

Invested Capital(Q: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=15.897 - 2.052 - ( 5.092 - max(0, 3.071 - 7.952+5.092))
=8.964

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=9.31 - 1.188 - ( 1.603 - max(0, 3 - 2.626+1.603))
=8.496

Note: The Operating Income data used here is two times the semi-annual (Sep. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Oxford BioDynamics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2025  Q: Sep. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-12.522/( ( (6.224 + max(0.807, 0)) + (5.41 + max(-0.925, 0)) )/ 2 )
=-12.522/( ( 7.031 + 5.41 )/ 2 )
=-12.522/6.2205
=-201.30 %

where Working Capital is:

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.723 + 0.345 + 0.792) - (2.052 + 0 + 0.00099999999999989)
=0.807

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.058 + 0.225 + 0.309) - (1.188 + 0 + 0.329)
=-0.925

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Sep. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Oxford BioDynamics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2025 )
=-13.043/12.278
=-106.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oxford BioDynamics EBIT Related Terms

Oxford BioDynamics EBIT Historical Data

* Premium members only.

The historical data trend for Oxford BioDynamics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oxford BioDynamics EBIT Chart

Oxford BioDynamics Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.77 -8.43 -12.99 -13.98 -12.80

Oxford BioDynamics Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.58 -5.56 -8.31 -6.78 -6.26

STU:LMQ vs TMO, DHR, IDXX: EBIT Comparison

For the Diagnostics & Research subindustry, Oxford BioDynamics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oxford BioDynamics EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Oxford BioDynamics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Oxford BioDynamics's EV-to-EBIT falls into.


Oxford BioDynamics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-13.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-13.04 Mil mean?
Oxford BioDynamics (STU:LMQ) has a EBIT of €-13.04 Mil as of Sep. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Oxford BioDynamics.
Is Oxford BioDynamics' EBIT too high?
Oxford BioDynamics' current EBIT is €-13.04 Mil.
How does Oxford BioDynamics' EBIT compare to TMO and DHR?
Oxford BioDynamics' EBIT of €-13.04 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Oxford BioDynamics. Oxford BioDynamics's current EBIT is €-13.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioDynamics stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioDynamics (STU:LMQ) is currently considered Possible Value Trap. The stock's GF Value™ is €0.01, compared to a current price of €0.00 — trading 95% below its estimated fair value. The current EBIT is €-13.04 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Oxford BioDynamics (STU:LMQ), the current EBIT is €-13.04 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oxford BioDynamics Business Description

Other Exchanges OXBOF:USAOBD:UK
Address John Smith Drive, 3140 Rowan Place, Oxford Business Park South, Oxford, GBR, OX4 2WB
Oxford BioDynamics PLC is a biotechnology company focused on advancing personalized healthcare through the development and commercialization of precision medicine tests for serious and impactful diseases. The company is engaged in the commercialisation of proprietary molecular diagnostics products and biomarker research and development. It has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. The company generates revenue from the sales of proprietary products and biomarker research and development. Geographically, it generates the maximum revenue from the USA.